Taysha Gene Therapies (TSHA): Valuation Perspectives After Regaining TSHA-102 Rights and FDA Breakthrough Status

Taysha Gene Therapies (TSHA) regained full rights to its TSHA-102 gene therapy program for Rett syndrome after the expiration of an agreement with Astellas. This change restores their strategic flexibility at the same time the therapy received FDA Breakthrough Therapy status.

See our latest analysis for Taysha Gene Therapies.

Following a wave of positive clinical news and the return of full control over its lead program, Taysha Gene Therapies’ share price has surged, rising 62.8% in the past month and 155% year-to-date. Despite a small pullback this week, the stock’s 1-year total shareholder return stands at 129%, marking strong momentum that investors are watching closely as pivotal trial milestones approach.

If momentum in biotech breakthroughs has your attention, consider the next discovery opportunity: See the full list for free.

With the stock already up sharply and analysts raising their forecasts, the key question now is whether Taysha shares are still undervalued or if the market has already priced in the company’s anticipated growth.

Most Popular Narrative: 50.3% Undervalued

Taysha Gene Therapies' most followed narrative assigns a fair value that is more than double its last close price of $4.72. This makes the stock appear deeply discounted relative to the projected outlook.

The analysts have a consensus price target of $6.55 for Taysha Gene Therapies based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0 and the most bearish reporting a price target of just $5.0.

Read the complete narrative.

Curious how they arrived at such a bold valuation for Taysha? The secret lies in ambitious growth forecasts and a profit outlook rarely seen in early-stage biotech. Want to see which key numbers truly drive this narrative and if they hold up to scrutiny? Push below the surface to uncover the full story behind this pricing.

Result: Fair Value of $9.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still key risks, including the challenge of gaining timely regulatory approval and the ongoing unprofitability, that could alter Taysha's trajectory.

Find out about the key risks to this Taysha Gene Therapies narrative.

Build Your Own Taysha Gene Therapies Narrative

Not convinced by the consensus or want to reach your own conclusions? Dive into the data and craft your personal valuation in just a few minutes. Do it your way.

A great starting point for your Taysha Gene Therapies research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Step ahead of the crowd by screening for opportunities most investors overlook. Tomorrow’s winners are waiting, so don’t let them slip by while others hesitate.

• Capture steady income streams when you check out these 18 dividend stocks with yields > 3% offering yields above 3% and strong payout histories.
• Spot untapped growth potential by checking these 24 AI penny stocks that are shaping the future with advanced artificial intelligence innovations.
• Uncover hidden value by searching these 878 undervalued stocks based on cash flows that trade below their true worth based on cash flow analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com